Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma

Docetaxel has shown remarkable radiosensitizing in vitro properties. In a previous phase I/II dose escalation study in non- small-cell lung cancer (NSCLC) we observed a high response rate after concomitant boost radiotherapy and weekly docetaxel. The maximum tolerated dose was 30 mg m(−2) week(−1)....

Descripción completa

Detalles Bibliográficos
Autores principales: Koukourakis, M I, Bahlitzanakis, N, Froudarakis, M, Giatromanolaki, A, Georgoulias, V, Koumiotaki, S, Christodoulou, M, Kyrias, G, Skarlatos, J, Kostantelos, J, Beroukas, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363119/
https://www.ncbi.nlm.nih.gov/pubmed/10468298
http://dx.doi.org/10.1038/sj.bjc.6690599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363119/
https://www.ncbi.nlm.nih.gov/pubmed/10468298
http://dx.doi.org/10.1038/sj.bjc.6690599

Ejemplares similares